The use of MEK inhibitor could reverse antiestrogen resistance in ER+ high grade serous ovarian cancer [49], and estrogen receptor pathway activity is associated with outcome in endometrial cancer [50]. The gene discussed is ESR1; the disease is ovarian serous adenocarcinoma.